

学会学術集会、2005.12.1-3、熊本

- 86) 神谷昌枝、石川雅子、井上洋士、折井佳穂里、加瀬まさよ、牧野麻由子、西村輝明、児玉憲一、辻麻里子；派遣カウンセリングの利用促進に関する研究 第一報：拠点病院医師によるエイズ派遣カウンセラー制度の認知度、評価及び問題点。第 19 回日本エイズ学会学術集会、2005.12.1-3、熊本
- 87) 神谷昌枝、石川雅子、井上洋士、折井佳穂里、加瀬まさよ、牧野麻由子、西村輝明、児玉憲一、辻麻里子；派遣カウンセリングの利用促進に関する研究 第二報：拠点病院医師が今後利用したいサービス。第 19 回日本エイズ学会学術集会、2005.12.1-3、熊本
- 88) 内野悌司、藤原良次、橋本則久、椎村和義、平岡 毅、藤井宝恵、塚本弥生、藤井輝久；ピア・カウンセラーと専門カウンセラーの協働に関する研究。第 19 回日本エイズ学会学術集会、2005.12.1-3、熊本
- 89) 小西加保留、石川雅子、菊池恵美子、葛田衣重；長期療養者の受け入れ体制に関する研究。第 19 回日本エイズ学会学術集会、2005.12.1-3、熊本
- 90) 若林チヒロ、生島 嗣；HIV 感染症をめぐる社会福祉分野の課題－就労を中心に。日本エイズ学会誌 7 (3): 189-192、2005.

#### 知的財産権の出願・登録状況（予定を含む。）

特許取得

なし

実用新案登録

なし

その他

なし

## 研究成果の刊行に関する一覧

## 研究成果の刊行に関する一覧表

### 雑誌・書籍

#### 主任研究者

- 1) X. Bi, H. Gatanaga, M. Tanaka, M. Honda, S. Ida, S. Kimura and S. Oka; Modified dynabeads method for enumerating CD4<sup>+</sup> T-lymphocyte count for widespread use in resource-limited situations. *J. Acquir. Immune. Defic. Syndr.* 38 (1): 1-4, 2005
- 2) H. Yamanaka, K. Teruya, M. Tanaka, Y. Kikuchi, T. Takahashi, S. Kimura, S. Oka and the HIV/Influenza Vaccine Study Team; Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. *J. Acquir. Immune. Defic Syndr.* 39 (2): 167-173, 2005
- 3) A. Kawana, K. Teruya, T. Hama, E. Kuroda, J. Sekiguchi, T. Kirikae, G. Naka, S. Kimura, T. Kuratsuji, H. Ohara and K. Kudo; Trial surveillance of cases with acute respiratory symptoms at IMCJ Hospital. *Jpn. J. Infect. Dis.* 58: 241-243, 2005
- 4) Y. Otsuka, T. Fujino, N. Mori, J. Sekiguchi, E. Toyota, K. Saruta, Y. Kikuchi, Y. Sasaki, A. Ajisawa, Y. Otsuka, H. Nagai, M. Takahara, H. Saka, T. Shirasaka, Y. Yamashita, M. Kiyosuke, H. Koga, S. Oka, S. Kimura, T. Mori, T. Kuratsuji and T. Kirikae; Survey of human immunodeficiency virus (HIV)-seropositive patients with mycobacterial infection in Japan. *J. Infect.* 51: 364-374, 2005
- 5) N. Mori, S. Hitomi, J. Nakajima, K. Okuzumi, A. Murakami and S. Kimura; Unselective use of intranasal mupirocin ointment for controlling propagation of methicillin-resistant *Staphylococcus aureus* in a thoracic surgery ward. *J. Infect. Chemother* 11: 231-233, 2005
- 6) Y. Hirabayashi, K. Tsuchiya, S. Kimura and S. Oka; Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. *Biomed. Chromatogr.* 20: 28-36, 2006
- 7) T. Yoshikawa, K. Kidouchi, S. Kimura, T. Okubo, J. Perry and J. Jagger; Needlestick injuries to the feet of Japanese healthcare workers; A culture-specific exposure risk. *Infection Control and Hospital Epidemiology* (in press)

#### 分担研究者

- 1) H. Yan, T. Chiba, N. Nomura, T. Takakura, Y. Kitamura, H. Miura, M. Nishizawa, M. Tatsumi, N. Yamamoto and W. Sugiura; A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity. *Antiviral Chemistry & Chemotherapy* 16: 363-373, 2005
- 2) R. Kantor, D.A. Katzenstein, B. Efron, A.P. Carvalho, B. Wynhoven, P. Cane, J. Clarke, S. Sirivichayakul, M.A. Soares, J. Snoeck, C. Pillay, H. Rudich, R. Rodrigues, A. Holguin, K. Ariyoshi, M.B. Bouzas, P. Cahn, W. Sugiura, V. Soriano, L.F. Brigido, Z. Grossman, L. Morris, A.M. Vandamme, A. Tanuri, P. Phanuphak, J.N. Weber, D. Pillay, P.R. Harrigan, R. Camacho, J.M. Schapiro and R.W. Shafer; Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

PLOS Medicine 2 (4): 325-337, 2005

- 3) K. Miyauchi, J. Komano, Y. Yokomaku, W. Sugiura, N. Yamamoto and Z. Matsuda; Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. *J. Virology* 79 (8): 4720-4729, 2005
- 4) K. Shiomi, R. Matsui, M. Isozaki, H. Chiba, T. Sugai, Y. Yamaguchi, R. Masuma, H. Tomoda, T. Chiba, H. Yan, Y. Kitamura, W. Sugiura, S. Omura and H. Tanaka; Fungal phenalenones inhibit HIV-1 integrase. *J. Antibiot.* 58 (1): 65-68, 2005
- 5) J. Snoeck, R. Kantor, R. W. Shafer, K. V. Laethem, K. Deforche, A. P. Carvalho, B. Wynhoven, M. A. Soares, P. Cane, J. Clarke, C. Pillay, S. Sirivichayakul, K. Ariyoshi, A. Holguin, H. Rudich, R. Rodrigues, M. B. Bouzas, F. B-Vezinet, C. Reid, P. Cahn, L. F. Brigido, Z. Grossman, V. Soriano, W. Sugiura, P. Phanuphak, L. Morris, J. Weber, D. Pillay, A. Tanuri, R. P. Harrigan, R. Camacho, J. M. Schapiro, D. Katzenstein and A-M. Vandamee; Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. *Antimicrob. Agents Chemother.* 50 (2): 694-701, 2006
- 6) 西澤雅子, 杉浦互; HIV-1 の薬剤耐性についての最近の知見. *BIO Clinica* 20 (8): 711-717, 2005
- 7) 杉浦互; 抗 HIV-1 薬剤の現状と薬剤開発の新たな展開. *ウイルス* 55 (1): 85-94, 2005
- 8) 杉浦互; 新規感染者における薬剤耐性 HIV 拡散の危機. *日本エイズ学会誌* 7: 117-120, 2005
- 9) 杉浦互, 瀧永博之, 田宮貞宏, 松田昌和, 松見信太郎, 蜂谷敦子, J.M. Coffin, 満屋裕明; 「薬剤耐性の新知見、基礎から臨床へ」を終えて. *日本エイズ学会誌* 7: 180-188, 2005
- 10) T. Hiura, H. Kagamu, S. Miura, A. Ishida, H. Tanaka, J. Tanaka, F. Gejyo and H. Yoshizawa; Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. *J. Immunology* 175: 5058-5066, 2005
- 11) F. Gejyo, N. Homma, N. Higuchi, K. Ataka, T. Teramura, B. Alchi, Y. Suzuki, S. Nishi, I. Narita and the Japanese Society of Nephrology; A novel type of encephalopathy associate with mushroom Sugihiratake ingestion in patients with chronic kidney diseases. *Kidney International* 68: 188-192, 2005
- 12) 内山正子; 針刺し・切創発生時の倫理的な対応. *Infection Control* 15 (1): 25-27, 2006
- 13) T. Hagiwara, J. Hattori and T. Kaneda; PNA-*in situ* hybridization method for detection of HIV-1 DNA in virus-infected cells and subsequent detection of cellular and viral proteins. *Methods in Molecular Biology* 326: 139-149, 2005
- 14) M. Takahashi, M. Yoshida, T. Oki, N. Okumura, T. Suzuki and T. Kaneda; Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. *Biol. Pharm. Bull.* 28 (7): 1286-1290, 2005
- 15) H. Nagai, K. Wada, T. Morishita, M. Utsumi, Y. Nishiyama and T. Kaneda; New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application. *J. Virological Methods* 124: 157-165, 2005
- 16) 高橋昌明, 吉田昌生, 大木剛, 奥村直哉, 鈴木達男, 金田次弘; HPLC におけるプロテアーゼ阻害剤アタザナビル の血中濃度測定法の開発. *日病薬誌* 41 (6): 731-734, 2005
- 17) 高橋昌明, 吉田昌生, 大木剛, 奥村直哉, 鈴木達男, 金田次弘; カレトラ™ 投与外来 HIV 感染患者における脂質異常とロピナビル血中濃度の評価. *日病薬誌* 41 (7): 876-876, 2005
- 18) 小西加保留; HIV 感染者の社会福祉施設利用受け入れに影響するサービス提供者側の要因について. *厚生 の指標* 52 (8): 8-14, 2005
- 19) 若林チヒロ, 生島嗣; HIV 感染者をめぐる社会福祉分野の課題—就労を中心に. *日本エイズ学会誌* 7:

## 2. 学会発表

### 主任研究者

- 1) 塚田訓久, 立川夏夫, 岡慎一, 木村哲, 小池和彦; HIV/HCV 重複感染血友病例に対する生体肝移植施行後の長期経過—HIV 感染症治療の観点から 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 2) 山中ひかる, 瀧永博之, 松岡佐織, P. Kosalarakla, 岡慎一, 木村哲; Nucleoside reverse transcriptase inhibitor (RTI) によるミトコンドリア毒性とヒト DNA polymerase  $\gamma$  (POLG) の遺伝子点変異. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 3) 林田康総, 瀧永博之, 白阪琢磨, 塚田弘樹, 松下修三, 木村哲, 岡慎一, EFV study group; Efavirenz の血中濃度に関わる cytochrome p450 2B6 の遺伝子多型とその頻度. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 4) 恩田順子, 上田晃弘, 原田壮平, 阿部泰尚, 福島篤仁, 横田恭子, 田沼順子, 矢崎博久, 本田美和子, 瀧永博之, 源河いくみ, 照屋勝治, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; HIV 感染者に合併した Burkitt Lymphoma/Burkitt like Lymphoma の 2 症例. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 5) 本田美和子, F. Drummond, M.R. Poehlman, 田沼順子, 源河いくみ, 瀧永博之, 照屋勝治, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; The SMART (strategies for management of anti-retroviral therapy) study enrolment update. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 6) 中野恵美子, 千綿かおる, 島田恵, 田上正, 岡慎一, 木村哲; HIV/AIDS 患者に対する外部歯科医療機関紹介事例について. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 7) 千綿かおる, 中野恵美子, 田上正, 岡慎一, 木村哲, 武田文; HIV 医療の進歩にともなう口腔状態の変化—1998 年と 2005 年の比較調査—. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 8) 保田典子, 三留よしな, 野崎威功真, 山中純子, 早川依里子, 福山由美, 大金美和, 山中ひかる, 照屋勝治, 菊池嘉, 岡慎一, 木村哲; 出血型もやもや病を合併した HIV 母子感染の 1 例. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 9) 上田晃弘, 阿部泰尚, 恩田順子, 横田恭子, 田沼順子, 矢崎博久, 本田美和子, 瀧永博之, 源河いくみ, 照屋勝治, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; LPV/r 内服患者における除脈性不整脈. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 10) 瀧永博之, 立川夏夫, 菊池嘉, 照屋勝治, 源河いくみ, 本田美和子, 田沼順子, 矢崎博久, 上田晃弘, 阿部泰尚, 横田恭子, 恩田順子, 木村哲, 岡慎一; Tenofovir disoproxil fumarate 投与と尿中  $\beta$  2-microglobulin. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 11) 矢崎博久, 恩田順子, 阿部泰尚, 上田晃弘, 横田恭子, 田沼順子, 本田美和子, 瀧永博之, 源河いくみ, 照屋勝治, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; 当センターにおける新規抗 HIV 療法の変遷について. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 12) 高野操, 池田和子, 大金美和, 島田恵, 岡田昌史, 岡慎一, 木村哲, 我妻ゆき子; 日本人 HIV 感染者における感染判明時の CD4 数と患者特性、抗体検査を受けた状況、既往歴との関連. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 13) 安岡彰, 鳴河宗聡, 舟田久, 照屋勝治, 源河いくみ, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; 一般的臨床検査値異常を見たときに HIV 感染症をどのくらい疑うべきか. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 14) 鈴木康弘, 瀧永博之, 立川夏夫, 菊池嘉, 照屋勝治, 本田美和子, 源河いくみ, 岡慎一, 木村哲; HIV-1 感染者、末梢静止 CD4T 細胞上の表面免疫複合体は病態、予後に深くかかわっている. 第 19 回

分担研究者

- 1) 照屋勝治, 恩田順子, 阿部泰尚, 横田恭子, 上田晃弘, 矢崎博久, 田沼順子, 瀧永博之, 本田美和子, 源河いくみ, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; 慢性 HIV 感染例における HAART 中断後の臨床経過に関する検討. 第 19 回日本エイズ学会. 熊本, 2005.12
- 2) 源河いくみ, 阿部泰尚, 恩田順子, 上田晃弘, 横田恭子, 矢崎博久, 田沼順子, 本田美和子, 瀧永博之, 照屋勝治, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; Atazanavir を含む抗 HIV 療法の 1 年間の治療成績. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 3) 立川夏夫, 菊池嘉, 照屋勝治, 源河いくみ, 瀧永博之, 本田美和子, 矢崎博久, 田沼順子, 上田晃弘, 岡慎一, 木村哲; AZT (zidovudine) 400mg を含む HAART 療法の有効性の検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 4) 田沼順子, 恩田順子, 阿部泰尚, 横田恭子, 上田晃弘, 矢崎博久, 本田美和子, 瀧永博之, 源河いくみ, 照屋勝治, 立川夏夫, 菊池嘉, 岡慎一, 木村哲; 急性 HIV 感染者に対する Structured Treatment Interruptions. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 5) N. Hasegawa, W. Sugiura, M. Matsuda, K. Mogushi, H. Tanaka and F. Ren; Inference of evolutionary forces driving HIV-1 drug-resistance acquisition under HAART using longitudinal HIV-1 protease gene samples. Antiviral Therapy 10:S114, June 7-11, 2005, Canada
- 6) T. Ueda, L. Myint, T. Shiino, M. Nishizawa, M. Matsuda, W. Sugiura; Analysis of interference and co-evolution between protease inhibitor resistant mutations and *gag* mutations. Antiviral Therapy 10:S116, June 7-11, 2005, Canada
- 7) 小池満, 三好洋, 井上靖之, 高橋正知, 山口洋子, 奥瀬千晃, 杉浦互, 中島秀喜; HIV/HBV coinfection における HBV 体制の検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 8) 浅黄司, 金田次弘, 伊部史朗, 松田昌和, 吉田繁, 津畑千佳子, 大家正義, 近藤真規子, 貞升健志, 瀧永博之, 正兼亜季, 佐藤克彦, 秦眞美, 溝上康司, 森治代, 南留美, 渡邊香奈子, 岡田清美, 杉浦互; HIV-1 薬剤耐性遺伝子検査法に関するアンケート調査. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 9) 西澤雅子, U. Parikh, 藤野真之, 松田昌和, 三浦秀佳, 加藤真吾, 山本直樹, 杉浦互; ヒト末梢血単核球を用いた K65R 獲得 HIV-1 の逆転写酵素阻害剤に対する感受性の解析. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 10) 杉浦互, 瀧永博之, 吉田繁, 千葉仁志, 浅黄司, 松田昌和, 岡慎一, 近藤真規子, 今井光信, 貞升健志, 長島真美, 伊部史朗, 金田次弘, 濱口元洋, 上田幹夫, 正兼亜季, 大家正義, 渡辺香奈子, 白阪琢磨, 山本善彦, 森治代, 小島洋子, 中桐逸博, 高田昇, 木村昭郎, 南留美, 山本政弘, 健山正男, 藤田次郎; 新規 HIV-1 感染者における薬剤耐性の頻度に関する全国疫学調査-2003 年から 2004 年にかけての報告. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 11) 大出裕高, 杉浦互, 星野忠次; コンピューター・シミュレーションによる CRF01\_AE NH1 N88S HIV-1 PR の NFV 耐性機構の解明. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 12) 仲宗根正, 高松純樹, 杉浦互, 佐藤裕徳, 山本伸二, H. Walid, 山本直樹; HIV-RT 薬剤感受性迅速試験法(半日)の開発. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 13) 駒野淳, 宮内浩典, L. Myint, 二橋悠子, 浦野恵美子, 松田善衛, 千葉智子, 三浦秀佳, 杉浦互, 山本直樹; Rapid propagation of low-fitness drug resistant mutants of HIV-1 by a-1 frameshift enhancer sparsomycin. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本

- 14) 加藤真吾, 田中理恵, 根岸昌功, 木内英, 花房秀次, 杉浦互; AZT は血漿中及び細胞内において確かに d4T に変換される. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 15) 小池満, 鈴木貴雄, 井上靖之, 山口洋子, 小池淳樹, 杉浦互, 高橋正知, 中島秀喜; HIV 関連リンパ腫における自己造血幹細胞採取の経験. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 16) 小池満, 高橋正知, 井上靖之, 山口洋子, 杉浦互, 中島秀喜; 当院における新規受診者の検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 17) 山元泰之, 山中晃, 内田泰斗, 尾形亨一, 福武勝幸, 杉浦互; 判定保留 HIV-1 抗体確認検査で確定し得ないとき. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 18) 藤本勝也, 橋野聡, 佐藤典宏, 山本聡, 西尾充史, 大野稔子, 渡部恵子, 田中淳司, 今村雅寛, 浅香正博, 小池隆夫; 抗 HIV 療法の脂質代謝に及ぼす影響~当院での検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 19) 岩尾憲明, 東梅友美, 太田秀一, 田中淳司, 今村雅寛; 血小板減少症の合併に対しステロイド治療が奏功した HIV/HBV/HCV 重複感染血友病 A の 1 例. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 20) 伊藤俊広, 佐藤功; 当院の性感染性 HIV/AIDS 患者における STD の実際. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 21) 宇佐美修, 肖鵬, 斉藤弘樹, 芦野有悟, 服部俊夫, 三木裕, 佐藤功, 服部真一郎, 仲宗根正, 原敬志; 東北地方の HIV 感染患者の臨床症状とウイルス特性. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 22) M. Yamada, I. Yamashita, N. Kawamoto, K. Nakano, C. Shimokawa, R. Wakimizu, H. Nojima, M. Yamashita, S. Nishide and M. Ueda; Practical Training for Nurses in HIV/AIDS Clinic --Experience in Hokuriku--. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 23) M. Ueda, M. Yamada, A. Masakane, N. Tsuji, M. Yamashita, C. Shimokawa, M. Miyata, Y. Imai, K. Kimura and M. Aoki; Growing Support Network for AIDS Medical Care and Prevention in Hokuriku Area. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 24) 小谷岳春, 上田幹夫, 青木眞; HBV 混合感染を来たした HIV 感染症患者に対する ART の経験. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 25) 山田三枝子, 山下美津江, 中宮久美子, 辻典子, 正兼亜季, 上田幹夫; 北陸ブロック拠点病院からの出前研修に関する実践報告-第 1 報-(医療機関). 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 26) 山下美津江, 山田三枝子, 中宮久美子, 辻典子, 正兼亜季, 上田幹夫; 北陸ブロック拠点病院からの出前研修に関する実践報告-第 2 報-(福祉施設等). 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 27) 正兼亜季, 辻典子, 山田三枝子, 小谷岳春, 木村和子, 上田幹夫; 北陸ブロック内保健所への HIV 抗体検査に関するアンケート調査結果. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 28) C. Tsubata, M. Higuchi, M. Takahashi, M. Oie, Y. Tanaka, F. Gejyo and M. Fujii; PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein is essential for the interleukin 2 independent growth induction of a T-cell line. *Retrovirology* (in press)
- 29) H. Tsukada, T. Nishibori, A. Imai, M. Makino, M. Uchiyama and F. Gejyo; HIV encephalopathy worsened during HAART. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 30) 高木律男, 山中正文, 下条文武, 塚田弘樹, 内山正子; HIV 感染者に対する歯科診療体制整備に向けて - HIV 感染者へのアンケートより-. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 31) 山中正文, 高木律男, 下条文武, 塚田弘樹, 内山正子; HIV 感染者に対する歯科診療体制整備に向けて

- 歯科医師へのアンケートより- 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 32) 坂上亜希子, 鈴木信明, 太田求磨, 田邊嘉也, 西堀武明, 竹田徹朗, 塚田弘樹, 下条文武; ネフローゼ症候群を来たした多剤耐性 HIV 感染症例に対する TDF の使用経験. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 33) 野口明子, 山田由美子, 奥村直哉, 菊池恵美子, 間宮均人, 濱口元洋; 名古屋医療センターにおける HAART 開始後の電話相談によるサポート支援の検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 34) 奥村直哉, 平野淳, 高橋昌明, 安岡彰, 間宮均人, 濱口元洋; 名古屋医療センターにおけるホスアンプレナビルの初回治療での使用経験. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 35) 菊池恵美子, 濱口元洋; 内なる偏見差別を乗り越えて- 他者による自己受容から自己による自己受容. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 36) 奥村直哉, 平野淳, 高橋昌明, 安岡彰, 間宮均人, 濱口元洋; 名古屋医療センターでの HAART における 1 日 1 回服用法の現状. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 37) 永井裕美, 水野善文, 加堂真由, 服部純子, 濱口元洋, 間宮均人, 西山幸廣, 金田次弘; HAART 著効例 HIV-1 感染患者のける残存 HIV-1 プロウイルス複製レベルの評価. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 38) S. Oda, Y. Shimoji, M. Nakata, Y. Shigeura, T. Uehira, T. Yasuo, R. Aoki, T. Enomoto and T. Shirasaka; Problems of foreign patients of PLWHA in Japan and their support system. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 39) T. Yasuo and T. Shirasaka; Psychological difficulties on deciding to live with HIV Case studies of psychotherapy with PLWHAs in Japan. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 40) 笹川淳, 酒井美緒, 牧江俊雄, 山本善彦, 上平朝子, 白阪琢磨; 当院で経験した進行性多巣性白質脳症(PML)についての検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 41) 上平朝子, 笹川淳, 森正彦, 牧江俊雄, 長谷川善一, 山本善彦, 下司有加, 織田幸子, 白阪琢磨; 当院における HBV/HIV 重複感染例についての検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 42) 下司有加, 織田幸子, 森田美揚子, 井上磨智子, 白阪琢磨; 受診中断患者の背景と受診再開への支援と経緯. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 43) 吉野宗宏, 永井聡子, 桑原健, 下司有加, 織田幸子, 笹川淳, 森正彦, 牧江俊雄, 長谷川善一, 山本善彦, 上平朝子, 白阪琢磨; 硫酸アタザナビルの至適血中濃度の検討. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 44) 白阪琢磨, 日笠聡, 岡慎一, 川戸美由紀, 吉崎和幸, 木村哲, 福武勝幸, 橋本修二; 血液製剤による HIV 感染者の調査成績 第 1 報 CD4 値、HIV-RNA 量と治療の現状と推移. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 45) 川戸美由紀, 橋本修二, 岡慎一, 吉崎和幸, 木村哲, 福武勝幸, 日笠聡, 白阪琢磨; 血液製剤による HIV 感染者の調査成績 第 2 報 投与歴を考慮した CD4 値、HIV-RNA 量と治療の変更との関連性. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 46) 篠澤圭子, 山元泰之, 青木眞, 味澤篤, 菊池嘉, 木村哲, 白阪琢磨, 高田昇, 花房秀次, 三間屋純一, 松宮輝彦, 福武勝幸; 国内未承認エイズ治療薬等を用いた HIV 感染症治療薬及び HIV 感染症至的治療法の開発に係る応用研究. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 47) 安尾利彦, 仲倉高広, 白阪琢磨; 当院の HIV 感染症患者における心理的支援へのニーズに関する分析. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 48) 山元泰之, 山中晃, 天野景裕, 福武勝幸, 坪井良治, 入澤亮吉, 斉藤万寿吉, 中村哲也, 根岸昌功,



- 白阪琢磨; HIV 感染症に対するエムトリシタビン投与による安全性と皮膚変色発現に関する検討. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 49) 永井聡子, 吉野宗宏, 桑原健, 下司有加, 織田幸子, 笹川淳, 森正彦, 長谷川善一, 牧江俊雄, 山本善彦, 上平朝子, 白阪琢磨; フマル酸テノホビルジソプロキシルの血中濃度とクレアチニンの関係. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 50) 桑原健, 吉野宗宏, 佐野俊彦, 小島賢一, 日笠聡, 白阪琢磨; 拠点病院における抗 HIV 療法と薬剤関連アンケート調査結果(第 2 報). 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 51) 浅野智子, 上平朝子, 下司有加, 織田幸子, 白阪琢磨; 当院における HIV 母子感染予防の現状について. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 52) 酒井美緒, 笹川淳, 森正彦, 牧江俊雄, 山本善彦, 上平朝子, 白阪琢磨; HIV 感染症患者の中樞神経疾患早期発見における頭部 MRI の意義. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 53) 藤井輝久, 高田昇, 河部康子, 石川暢恒, 木村昭郎; 広島大学病院における HIV/HCV 重複感染患者の実態. 第 19 回日本エイズ学会, 2005.12.1-3, 熊本
- 54) 石川暢恒, 高田昇, 河部康子, 喜花伸子, 大江昌恵, 大下由美, 畝井浩子, 藤井輝久, 木村昭郎, 杉浦互; 半年以内に感染したと推定される HIV 感染症の 9 例. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 55) R. Minami, M Yamamoto, A. Horita, T. Miyamura, K. Izutsu and E. Suematsu; Elevated serum levels of RCAS 1 are associated with a poor recovery of the CD4+T cell count after ART in HIV-1-infected patients. AIDS Research (in press)
- 56) R. Minami, M. Yamamoto, A. Horita, T. Miyamura, K. Izutsu and E. Suematsu; HIV-Tat protein increased the expression of apoptosis-associated protein RCAS1 in CD4+ cells and monocytes. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 57) S. Ichikawa, M. Satoh, M. Utsumi, T. Onizuka, M. Yamamoto and H. Kimura; Preventive enlightenment by gay CBO in Japan. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 58) 南留美, 山本政弘; 高熱を繰り返したのち発症した HIV-1 陽性 HHV-8 関連 Castleman 病の一例. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 59) 辻麻里子, 山本政弘, 城崎真弓, 井上緑, 山田淳子, 本松由紀, 矢永由里子, 佐野正; 医療と行政による検査/相談/医療の環境改善を目的とした取り組み—多職種による講義と実践の研修会を通して—. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 60) 前田憲昭, 加藤真吾, 田中理恵, 口勝規, 柿澤卓, 泉福英信, 宇佐美雄司; 唾液中の HIV-RNA 測定方法の評価. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 61) 田上正, 池田正一, 小森康雄, 高木律男, 宮田勝, 連利隆, 北川善政, 山口泰, 玉城廣保, 吉野宏; HIV 感染者の唾液中の HIV-RNA 定量. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 62) 吉川博政, 樋口勝規, 田上正, 山口泰; HIV 感染者における歯科医療の連携に関する研究. 第 19 回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 63) F. Kishigami, M. Shimada, M. Nishigaki, Y. Yamada, K. Takeda, Y. Fukuyama, M. Ogane, K. Ikeda, K. Kazuma and S. Kimura; Study on the consultation activities of HIV/AIDS coordinator nurses by telephone in an AIDS clinical center in Japan. Journal of the Association of Nurses in AIDS Care (in press)
- 64) M. Shimada, M. Ogane, Y. Fukuyama, K. Takeda, Y. Yamada, K. Ikeda, S. Oka, S. Kimura, K. Kazuma and S. Kawamura; A study to prepare a pre-antiretroviral therapy (ART) assessment protocol to lead good adherence to ART. 7<sup>th</sup> ICAAP, July 1-5, 2005, Kobe
- 65) 畑中祐子, 大金美和, 池田和子, 山田由紀, 武田謙治, 島田恵, 石垣今日子, 岡慎一, 木村哲; HIV/AIDS患者の在宅療養支援導入後の状況. 第19回日本エイズ学会, 2005.12.1-3, 熊本

- 66) 武田謙治, 島田恵, 池田和子, 大金美和, 山田由紀, 畑中裕子, 石垣今日子, 岡慎一, 木村哲; エイズ治療・研究開発センターから国内他医療機関に紹介した連携事例の背景と療養継続支援の検討. 第19回日本エイズ学会, 2005.12.1-3, 熊本
- 67) 山本法子, 中島由美, 北脇亜衣, 池田和子, 島田恵, 小野瀬友子; 当センターにおける初診時直接入院成人患者の特徴と転帰の関連—病期別に比較して—. 第19回日本エイズ学会, 2005.12.1-3, 熊本
- 68) 大金美和, 山田由紀, 石垣今日子, 畑中裕子, 武田謙治, 池田和子, 島田恵, 野口明子, 山田由美子, 谷口晴記, 山田里佳, 嶋貴子, 川戸美由紀, 源河いくみ, 岡慎一, 木村哲; 女性患者の療養支援に関する基礎的調査. 第19回日本エイズ学会, 2005.12.1-3, 熊本
- 69) 池田和子, 山田由紀, 武田謙治, 大金美和, 畑中祐子, 石垣今日子, 島田恵, 岡慎一, 木村哲; 当センター成人患者におけるMDOT (Modified Directly Observed Therapy) の検討. 第19回日本エイズ学会, 2005.12.1-3, 熊本
- 70) 島田恵, 今井敦子, 内山正子, 山田三枝子, 山下郁江, 人見公代, 星屋寿賀子, 大金美和, 池田和子, 数間恵子, 川村佐和子; 抗HIV療法を行う患者の外來支援に関するプロトコールの改訂に関する検討. 第19回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 71) 山中京子, 岳中美穂, 岡本学榎, 本てる子, 土居加寿子, 横田恵子, HIV交代検査前後の個別相談—CHARMが実施した土曜抗体検査における相談活動の分析より—. 第19回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 72) 神谷昌枝, 石川雅子, 井上洋士, 折井佳穂里, 加瀬まさよ, 牧野麻由子, 西村輝明, 児玉憲一, 辻麻里子; 派遣カウンセリングの利用促進に関する研究 第一報: 拠点病院医師によるエイズ派遣カウンセラー制度の認知度、評価及び問題点. 第19回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 73) 神谷昌枝, 石川雅子, 井上洋士, 折井佳穂里, 加瀬まさよ, 牧野麻由子, 西村輝明, 児玉憲一, 辻麻里子; 派遣カウンセリングの利用促進に関する研究 第二報: 拠点病院医師が今後利用したいサービス. 第19回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 74) 内野悌司, 藤原良次, 橋本則久, 椎村和義, 平岡毅, 藤井宝恵, 塚本弥生, 藤井輝久; ピア・カウンセラーと専門カウンセラーの協働に関する研究. 第19回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 75) 小西加保留, 石川雅子, 菊池恵美子, 葛田衣重; 長期療養者の受け入れ体制に関する研究. 第19回日本エイズ学会学術集会, 2005.12.1-3, 熊本
- 76) 若林チヒロ, 生島嗣; HIV感染症をめぐる社会福祉分野の課題—就労を中心に—. 日本エイズ学会誌 7 (3): 189-192, 2005

## Modified Dynabeads Method for Enumerating CD4<sup>+</sup> T-Lymphocyte Count for Widespread Use in Resource-Limited Situations

Xiuqiong Bi,\*† Hiroyuki Gatanaga,\* Mari Tanaka,\* Miwako Honda,\* Setsuko Ida,\* Satoshi Kimura,\* and Shinichi Oka\*

**Summary:** The Dynabeads method showed the potential for enumerating CD4<sup>+</sup> T lymphocytes (CD4 count) in HIV-1-infected individuals. The large volume of Dynabeads required for 1 sample and complex procedure made the method expensive and not easy for use, however. To decrease the cost and simplify the procedure, we reduced the volume of the Dynabeads, added wash times, and skipped over the staining step so as to count the CD4 cells directly under an optical microscope. The CD4 count of 246 blood samples using our modified Dynabeads method (DynabeadsCD4) showed a significant correlation with that obtained by flow cytometry (FlowcytoCD4) ( $r = 0.91$  [ $P < 0.0001$ ]; slope = 1.03, intercept = -16). The sensitivity and specificity for a CD4 count less than 200 cells/ $\mu\text{L}$  were 79% and 94%, and for a CD4 count less than 350 cells/ $\mu\text{L}$ , the sensitivity and specificity were 95% and 88%, respectively. The positive and negative predictive values for a CD4 count less than 350 cells/ $\mu\text{L}$  were 97% and 83%, respectively. The systematic error was 8 cells/ $\mu\text{L}$  (95% confidence interval [CI]: 0.4–16). The cost of Dynabeads for 1 sample was less than \$1.00; thus, the estimated cost per DynabeadsCD4 test is less than \$3.00, including the cost of other disposable materials. Our modified method is simple, economic, and accurate enough to monitor antiretroviral therapy in resource-limited situations.

**Key Words:** CD4, monitoring, Dynabeads, resource-limited situations

(*J Acquir Immune Defic Syndr* 2005;38:1–4)

The CD4<sup>+</sup> T-lymphocyte count (CD4 count) is an important surrogate marker for the clinical course of HIV infection, such as initiation of prophylactic treatment of opportunistic infections, initiation of antiretroviral therapy (ART), and

monitoring the response to ART.<sup>1–4</sup> In developed countries, the CD4 count is usually measured by flow cytometry, which is considered to be the standard reference method.<sup>3,4</sup> In resource-limited areas, however, flow cytometry is available only in limited settings such as tertiary medical centers because it requires expensive reagents and well-trained technicians. Furthermore, equipment maintenance is another difficult issue, because a technical support system is needed in areas afflicted with frequent electrical power failures, which could potentially cause machine-related problems.

In recent years, lower cost and less technically demanding methods for enumerating CD4 cells have been tried but have not been used widely even in resource-limited settings for various reasons.<sup>4,5</sup> In the World Health Organization (WHO) guidelines for treatment of HIV-infected individuals in resource-limited environments, a total lymphocyte count (TLC) of 1200 cells/ $\mu\text{L}$  is recommended to represent a CD4 count threshold of 200 cells/ $\mu\text{L}$  in making a decision regarding therapy when the CD4 count is unavailable.<sup>1</sup> In addition, various research groups have recommended the use of a TLC,<sup>5</sup> absolute lymphocyte count or TLC,<sup>6</sup> and TLC combined with hemoglobin measurement<sup>7</sup> as surrogate markers for monitoring ART. These studies suggested that the lymphocyte count might have some value in monitoring ART. The lymphocyte count is readily available and inexpensive, but it is not sufficiently adequate to predict the absolute CD4 count in many settings.<sup>4</sup>

Among several low-cost and less technically demanding methods,<sup>8–15</sup> the Dynabeads assay, which uses magnetic particles coated with a monoclonal antibody to CD4 to capture CD4<sup>+</sup> cells, seems to be a good candidate as an alternative to flow cytometry based on its good correlation with the results of flow cytometry.<sup>8,10,11,13</sup> According to the protocol recommended by the manufacturer, however, CD4 and CD8 cells are enumerated at the same time using a large volume of Dynabeads. The large volume of Dynabeads used in each assay is also relatively expensive (approximately \$5), particularly for poor settings. In addition, division of the samples into 2 aliquots during the procedure might jeopardize the accuracy of the results. Moreover, in this assay, the cells are lysed and nuclei are stained to count them, which makes the operation complex.

For monitoring ART in HIV infections, only the CD4 component is necessary and only the CD4 count (not CD8 count) is mentioned in ART guidelines.<sup>1,2</sup> For this reason,

Received for publication May 31, 2004; accepted September 14, 2004.

From the \*AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan; and †Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Supported in part by a grant-in-aid for AIDS Research from the Ministry of Health, Labor, and Welfare of Japan (H15-AIDS-001, H15-International Medical Cooperative Study-03), by the Organization of Pharmaceutical Safety and Research (01-4), and by the Japanese Foundation for AIDS Prevention (X.B.).

Reprints: Shinichi Oka, AIDS Clinical Center, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan (e-mail: oka@imcj.hosp.go.jp).

Copyright © 2004 by Lippincott Williams & Wilkins

further modifications are needed for the expanded use of the CD4 count in resource-limited areas. In the present study, we modified the protocol to make it simple and inexpensive so that it could be applied widely in resource-limited facilities.

## MATERIALS AND METHODS

### Study Population and CD4 Enumeration

This study included 242 adult patients infected with HIV-1 who regularly consulted the AIDS Clinical Center of the International Medical Center of Japan between June and October 2003. The inclusion criteria were a CD4 count less than 1000 cells/ $\mu$ L and consent granted to participate in the study. Patient age ranged from 20 to 78 years (mean  $\pm$  SD:  $40 \pm 11.5$ ). A total of 315 blood samples were collected using EDTA-containing tubes and tested for CD4 count within 4 hours by flow cytometry (FlowcytoCD4; Coulter-EPICS XL-MCL, Beckman-Coulter, Fullerton, CA) with CD45-fluorescein isothiocyanate (FITC)/CD4-phycoerythrin (RD1)/CD8-phycoerythrin-Texas Red (ECD)/CD3-phycoerythrin-cyanin 5.1 (PC5) (Beckman-Coulter). The CD4 cell count in the rest of the blood sample was enumerated using Dynabeads (Dynabeads CD4; Dynal Biotech ASA, Oslo, Norway) within 24 hours. When different protocols such as 25- $\mu$ L and 5- $\mu$ L volumes of CD4 Dynabeads or 10 and 30 minutes of incubation time were compared, the same sample was used in each experiment.

### Modified Protocol (Original Protocol) of the Dynabeads Method

A well-mixed whole-blood sample (125  $\mu$ L) was placed into a 1.5-mL microtube containing 375  $\mu$ L (350  $\mu$ L) of buffer (0.1% bovine serum albumin in phosphate-buffered saline [PBS]). CD14 Dynabeads were suspended with buffer (1:1 diluted buffer); 5  $\mu$ L (25  $\mu$ L) of CD14 Dynabeads was then added to the microtube containing the blood sample and the tube was inverted several times and then incubated in Dynal MX-1 for 10 minutes. The tube was spun down in a microcentrifuge and then placed in magnetic particle concentration for microcentrifuge tubes (Dynal MPC-S) (6 tubes per batch) for 2 minutes, followed by transfer of the entire volume (division into 2 200- $\mu$ L aliquots) of monocyte-depleted blood into a new microtube. In the next step, 5  $\mu$ L (25  $\mu$ L) of CD4 Dynabeads was added to the tube and incubated in Dynal MX-1 for 30 minutes (10 minutes). The cells were washed with 500  $\mu$ L of buffer, vortexed gently, and spun down; the tube was then placed in Dynal MPC-S for 2 minutes, the wash buffer was discarded, and the tube was removed from the Dynal MPC-S. The cells were washed 3 more times (once), resuspended by adding 125  $\mu$ L of buffer, and kept at 4°C until counting (50  $\mu$ L of lysing solution was added, followed by thorough vortexing for resuspension, and the cells were allowed to stand for 5 minutes, after which 50  $\mu$ L of acridine orange staining solution was added and the sample was kept in darkness until counting). Finally, the sample was vortexed well, 10  $\mu$ L of cells was applied to a hemocytometer, and the mononuclear cells with attached Dynabeads were counted as

CD4<sup>+</sup> cells under a light microscope (the number of nuclei was determined under a fluorescence microscope). After reducing the volume of CD4 Dynabeads, it was not difficult to count the CD4 cells under an optical microscope, even without staining. All procedures were performed at room temperature at approximately 23°C. All Dynabeads-related equipments and reagents were products of Dynal Biotech ASA.

### Statistical Analysis

All data are expressed as mean  $\pm$  SD. StatView v5.0 software was used to analyze the correlation and single linear regression between DynabeadsCD4 and FlowcytoCD4. *P* values were calculated by 2-sided test and considered as significant if at a level less than 5%. All confidence intervals were 2-sided, with a significant level of 5%.

## RESULTS

First, we examined the influence of a reduced volume of CD14 (from 12.5  $\mu$ L to 5  $\mu$ L) Dynabeads on monocyte depletion. The percentage of monocytes in 5 blood samples was analyzed by flow cytometry before and after treatment with 5  $\mu$ L of CD14 Dynabeads. The result showed that 5  $\mu$ L of CD14 Dynabeads deleted 92.4% to 97.5% (average = 95.6%) of monocytes from 125  $\mu$ L of whole blood. The remaining experiments were performed using 5  $\mu$ L of CD14 Dynabeads. Next, we examined the influence of a reduced volume of CD4 Dynabeads on the CD4 count in 23 samples. The volume of CD4 Dynabeads was reduced from 25  $\mu$ L to 5  $\mu$ L, but the incubation time was still 10 minutes (like that of original protocol), which we called modified protocol 1. CD4 counts by the original protocol and modified protocol 1 correlated significantly with those determined by flow cytometry: DynabeadsCD4 by the original protocol ( $r = 0.90$  [ $P < 0.0001$ ]; slope = 1.05, intercept = -32) and DynabeadsCD4 by modified protocol 1 ( $r = 0.92$  [ $P < 0.0001$ ]; slope = 1.05, intercept = 26). These results indicated that DynabeadsCD4 obtained by using the reduced volume of CD4 Dynabeads with a 10-minute CD4 separation correlated well with FlowcytoCD4. When the number of samples was increased to 56, however, the mean DynabeadsCD4 of 56 samples by modified protocol 1 was  $269 \pm 140$  cells/ $\mu$ L compared with a mean FlowcytoCD4 of  $336 \pm 178$  cells/ $\mu$ L (Table 1). The difference was -67 cells/ $\mu$ L ( $P < 0.0001$ ). This result suggested that the 10-minute CD4 separation time was too short. We then examined the effect using a reduced volume of Dynabeads and a different incubation time.

Next, with 5  $\mu$ L of CD4 Dynabeads, we lengthened the CD4 separation time from 10 minutes to 30 minutes in 34 samples. The correlations between DynabeadsCD4 and FlowcytoCD4 were  $r = 0.91$  ( $P < 0.0001$ ) and  $r = 0.94$  ( $P < 0.0001$ ), with slopes of 1.05 and 1.0 and intercepts of 22 and 8, for 10 and 30 minutes of incubation time, respectively. The mean difference with flowcytoCD4 was -32 cells/ $\mu$ L ( $P = 0.008$ ) and -8 cells/ $\mu$ L ( $P = 0.42$ ), respectively. According to these data, the 30-minute incubation time for CD4 separation yielded a better result than that of the 10-minute incubation time. We then fixed the protocol as 5  $\mu$ L of CD14 Dynabeads with 10 minutes of incubation time and 5  $\mu$ L of CD4

**TABLE 1.** DynabeadsCD4 Determined by Different Protocols Compared with FlowcytoCD4

Protocol	Mean ± SD (Cells/μL)		Mean Difference		Regression Line		
	DynabeadsCD4	FlowcytoCD4	Cells/μL (95% CI)	P	Intercept	Slope	r <sup>2</sup>
Original (n = 59)	364 ± 166	372 ± 193	-8 (-32 to 16)	0.521	-2	1.026	0.775
Modified 1 (n = 56)*	269 ± 140	336 ± 178	-67 (-93 to -41)	<0.0001	50	1.061	0.698
Modified 2 (n = 246)†	262 ± 136	254 ± 154	8 (0.4 to 16)	0.0396	-16	1.031	0.829

†Modified 2 (the final one): modified protocol with 30 minutes of CD4 separation.  
 \*Modified 1: modified protocol with 10 minutes of CD4 separation.  
 P > 0.05 for all intercepts, P < 0.0001 for all slopes and r<sup>2</sup>.

Dynabeads with 30 minutes incubation time (which we called modified protocol 2) and tested 246 samples. DynabeadsCD4 showed a significant correlation with FlowcytoCD4 (r = 0.91 [P < 0.0001]; slope = 1.03, intercept = -16; Fig. 1). At less than 200 cells/μL, the sensitivity and specificity of DynabeadsCD4 compared with FlowcytoCD4 were 79% and 94%, respectively, and at less than 350 cells/μL, the sensitivity and specificity were 95% and 88%, respectively. The mean DynabeadsCD4 was 262 ± 135 cells/μL and that of FlowcytoCD4 was 254 ± 154 cells/μL (see Table 1). The difference in the mean values was 8 cells/μL (95% confidence interval [CI]: 0.4–16; P = 0.04), with a random error of 64 cells/μL. The positive and negative predictive values of DynabeadsCD4 and FlowcytoCD4 for less than 200 cells/μL and less than 350 cells/μL were 90% and 87% and 97% and 83%, respectively. Other factors (eg, on therapy vs. off therapy, male vs. female) had no influence on DynabeadsCD4 (data not shown).

Table 2 shows the results of a comparison between the original protocol and our modified protocol. In our modified protocol, volumes of CD14 and CD4 Dynabeads were reduced from 12.5 μL and 25 μL, respectively, to 5 μL each against 125 μL of whole blood. Accordingly, the cost of the Dynabeads test decreased from \$2.84 to \$0.89. The incubation time for CD4 separation was prolonged to 30 minutes to obtain a better yield. In our protocol, after monocyte depletion, we transferred all treated blood to a new microtube for CD4 cell

separation because we did not consider the CD8 count. We also skipped over lysis and nuclear staining steps so as to simplify the procedure.


### DISCUSSION

To attain the “3 by 5” goal of effective ART promoted by the WHO, precise monitoring of ART is indispensable. Low cost, in addition to good accuracy, is thus an important issue. In this regard, maintenance of a “high-tech” machine for long-term monitoring may be impossible. The Dynabeads method is currently used as an alternative method to flow cytometry for CD4 count in a number of countries. In this study, we successfully modified the protocol of the Dynabeads method to make it more suitable in resource-limited areas with 2 goals in mind: reasonable cost and sufficient accuracy.

**TABLE 2.** Comparison Between the Original Protocol and Modified Protocol 2 for Enumeration of CD4 Count

Step	Original Protocol	Modified Protocol 2
Buffer (μL)	350	375
Blood (μL)	125	125
CD14 Dynabeads (μL)	25 (1:1 dilution)	5
Incubation temperature (°C)	RT	RT
Incubation duration (min)	10	10
Monocyte-depleted supernatant (μL)	200*	505†
CD4 Dynabeads (μL)	25	5
Incubation temperature (°C)	RT	RT
Incubation duration (min)	10	30
Repeat of washing (total min)	2 (10 min)	4 (20 min)
Staining time (min)	5 min	—
Resuspension volume (μL)	—	125
Time of total experiment per sample (min)	50	75
Samples comfortably analyzed per operator	12–18	12–18
Cost of CD14 Dynabeads (\$)	1.63	0.65
Cost of CD4 Dynabeads (\$)	1.21	0.24
Total cost of Dynabeads (\$)	2.84	0.89

\*Transferring 200 μL to a new tube.  
 †Transferring the entire volume to a new tube.  
 Values are for 1 test.  
 RT indicates room temperature (approximately 23°C).



FlowcytoCD4 = -16.484 + 1.031 × DynabeadsCD4; r<sup>2</sup> = 0.829

**FIGURE 1.** Correlation analysis of CD4<sup>+</sup> T-lymphocyte count (CD4 count) using Dynabeads method and CD4 count using flow cytometry.

In the present study, DynabeadsCD4 obtained by using the original protocol also showed a good result (see Table 1). During the operation, we found 2 problems with the original protocol, however. One was the transfer of 200  $\mu$ L of blood from 500  $\mu$ L of blood to a new tube after monocyte depletion. This step might lead to inaccurate results because we could not mix the blood well while the tube was on the Dynal MPC-S. The other was that too many free Dynabeads (which did not attach to CD4 cells) and red blood cells were identified when the cells were counted under a light microscope. This might be the reason for recommending lysis of the cells, staining the nuclei, and using a fluorescent microscope in the last step of the original protocol. In our modified protocol, the entire sample was transferred to a new tube after monocyte depletion. The number of free Dynabeads decreased after the volume of CD4 Dynabeads was reduced. Furthermore, we washed the sample 4 times after CD4 cell separation in spite of the original protocol recommending washing only twice. The red blood cells could be almost completely removed by 4 washes, especially when the washing buffer had been discarded completely at each wash. These modifications made a direct count under a light microscope possible.

After reduction of the volume of Dynabeads used in the assay, the cost of reagents used for analysis of 1 sample decreased to less than \$1.00. Thus, the total cost of 1 CD4 count, including other disposable materials such as syringes, tubes, and tips, could be less than \$3.00.

In conclusion, the present study demonstrated that our final modified protocol of Dynabeads assay could be used as a good alternative to flow cytometry with sufficient accuracy, reliability, and simplicity at a reasonable cost. Therefore, the assay could be suitable for monitoring ART in resource-limited settings.

#### ACKNOWLEDGMENTS

The authors thank Naomi Wakasugi (International Medical Center of Japan) and Kenji Tamura (WHO) for their helpful suggestions and encouragement during the study.

#### REFERENCES

1. World Health Organization. Scaling up antiretroviral therapy in resource limited settings: guidelines for a public health approach. Available at: <http://www.who.int/hiv/>. Accessed April 2002.
2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: <http://AIDSinfo.nih.gov>. Accessed July 14, 2003.
3. Brando B, Barnett D, Janossy G, et al. Cytofluorimetric methods for assessing absolute numbers of cell subsets in blood. *Cytometry*. 2000; 42:327–346.
4. Crowe S, Turnbull S, Oelrichs R, et al. Monitoring of human immunodeficiency virus infection in resource-constrained countries. *Clin Infect Dis*. 2003;37(Suppl 1):S25–S35.
5. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. *AIDS*. 2003;17:541–545.
6. Jacobson AM, Liu L, Khayam-Bashi H, et al. Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. *AIDS*. 2003;17:917–919.
7. Spacek AL, Griswold M, Quinn CT, et al. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. *AIDS*. 2003;17:1311–1317.
8. Diabougoua S, Chazallon C, Kazatchkine MD, et al. Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study. *AIDS*. 2003;17:2201–2208.
9. Brinchmann JE, Leivestad T, Vartdal F. Quantification of lymphocyte subsets based on cells directly from blood. *J Immunogenet*. 1989;16:177–183.
10. Didier J, Kazatchkine M, Demouchy C, et al. Comparative assessment of five alternative methods for CD4 T-lymphocyte enumeration for implementation in developing countries. *J Acquir Immune Defic Syndr*. 2001; 26:193–195.
11. Lyamuya EF, Kagoma C, Mbena EC, et al. Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. *J Immunol Methods*. 1996;195:103–112.
12. Nicholson JK, Velleca W, Jubert S, et al. Evaluation of alternative CD4 technologies for the enumeration of CD4 lymphocyte. *J Immunol Methods*. 1994;177:43–54.
13. Lyamuya EF, Schechter M, Echeverria de Perez G, et al. Multicentre evaluation of alternative methods for CD4 lymphocyte determination [abstract Mo.A.513]. Presented at the International AIDS Conference, Vancouver, July 1996.
14. Carella AV, Moss MW, Provost V, et al. A manual bead assay for the determination of absolute CD4+ and CD8+ lymphocyte counts in human immunodeficiency virus-infected individuals. *Clin Diagn Lab Immunol*. 1995;2:623–625.
15. Gaudernack G, Lundin KE. Rapid immunomagnetic phenotyping of cells. *J Immunogenet*. 1989;16:169–175.

# Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-Infected Patients

Hikaru Yamanaka, MD,\*† Katsuji Teruya, MD,\* Mari Tanaka, PhD,\*  
Yoshimi Kikuchi, MD,\* Takao Takahashi, MD,† Satoshi Kimura, MD,\*  
Shinichi Oka, MD,\* and the HIV/Influenza Vaccine Study Team

**Summary:** Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine. From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%–10%] in vaccinated vs. 21.2% [CI: 13%–35%] in nonvaccinated persons,  $P < 0.001$ ; relative risk = 0.29 [CI: 0.14–0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count  $>200$  cells/ $\mu$ L compared with those with a CD4 count  $<200$  cells/ $\mu$ L ( $P < 0.05$ ). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART ( $P < 0.01$ ), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.

**Key Words:** HIV-1, influenza, vaccination, antibody response, specific CD4

(*J Acquir Immune Defic Syndr* 2005;39:167–173)

After the recent approval of various anti-influenza drugs and rapid diagnosis kits for influenza infection by the Ministry of Health, Labor, and Welfare of Japan, it has become easier to diagnose this infection. Along with the developments in diagnostic methods and treatment of the infection, influenza

vaccination programs have been actively applied in HIV-1-infected individuals. Influenza virus infection may be more prolonged in individuals with immunodeficiency<sup>1</sup> and can cause a transient increase in plasma HIV-1 viral load (VL)<sup>2</sup> that might become relevant to the clinical course of HIV-1 infection.<sup>2,3</sup> Therefore, influenza vaccine has been generally recommended for HIV-1-infected patients,<sup>4–6</sup> as is already stated in the guidelines of the Advisory Committee on Immunization Practices.<sup>7</sup> Few studies have reported the protective effect of such vaccination in patients with HIV-1 infection, however. Previous studies demonstrated that the number of CD4 T cells (CD4 count) could predict the efficacy of and/or antibody response to the vaccine but did not clearly demonstrate the correlation between the vaccine efficacy and HIV VL.<sup>1,8–15</sup>

Activated memory CD4<sup>+</sup> T cells are the predominant target of HIV-1,<sup>16</sup> and the antibody response to hemagglutinin (HA) is T-cell dependent.<sup>17–19</sup> Therefore, highly active antiretroviral therapy (HAART) may reconstitute the immune function of not only the antibody responses but T helper (Th)–cell responses. In this large prospective clinical study, we investigated the clinical efficacy of influenza vaccine in HIV-1-infected patients and correlated it with the immune response to the vaccine as determined by increased antibody titer and/or HA-specific CD4 T cells.

## MATERIALS AND METHODS

### Study Design and Participants

A 0.5-mL dose of single-shot trivalent influenza subunit vaccine, which contains 15  $\mu$ g of influenza virus strains A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Shanton/7/87, was prepared for adults in the 2002 through 2003 winter season in Japan. All HIV-1-infected patients who consulted the outpatient clinic of the AIDS Clinical Center at the International Medical Center of Japan from November 1 to December 27, 2002 were advised to receive the vaccine, although the final decision was left to the individual. In previous seasons, nearly half of HIV-1-infected patients received influenza vaccine in our clinic. This study was designed to be prospective in nature but nonrandomized. Only individuals, vaccinated and nonvaccinated, who understood the purpose of the study were enrolled, without any incentives. To keep selective bias to a minimum, all vaccinated and consecutive first-come 100 nonvaccinated patients were asked to participate in this study. All study participants gave

Received for publication July 7, 2004; accepted March 16, 2005.

From the \*AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan; and †Department of Pediatrics, School of Medicine, Keio University, Tokyo, Japan.

Supported in part by a grant for AIDS Research from the Ministry of Health, Labor, and Welfare of Japan (H15-AIDS-001) and by the Japanese Foundation for AIDS Prevention (H.Yamanaka).

Reprints: Shinichi Oka, AIDS Clinical Center, International Medical Center of Japan, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan (e-mail: oka@imej.hosp.go.jp).

Copyright © 2005 by Lippincott Williams & Wilkins

informed consent, and the institutional ethical committee approved this study (protocol IMCJ-141). Twenty-six hospital staff members who were vaccinated with the same vaccine batch were enrolled as healthy immunized controls after consenting to participate in this study. Among them, 4 had no anti-influenza antibodies before vaccination. All participants were asked to visit to our clinic at least at week 0, 8, and/or 16 after enrollment to allow the withdrawal of 17 mL of blood at each visit for analysis of immunologic responses and routine examinations, including CD4 count and HIV VL.

### Definition and Diagnosis of Influenza Virus Infection

In this study, influenza infection (illness) was defined if the patient had flulike symptoms associated with at least 1 adjunct diagnosis such as a serologic or virologic diagnosis. Flulike symptoms were defined as a fever of  $\geq 38.0^{\circ}\text{C}$  combined with 2 of the following 5 clinical symptoms: cough, rhinitis, myalgia, sore throat, and headache. All participants were asked to visit the clinic if they developed flulike symptoms. To avoid a bias in the clinical diagnosis, a history of influenza vaccination was written out on a separate colored sheet, which was removed from medical records before the outpatient clinic physician attended and examined the patient. The serologic diagnosis was defined as a  $>4$ -fold rise in anti-influenza antibody titer compared with before and 4 weeks after the symptoms. In addition, a change of the antibody titer from  $<10$  to 40 U was defined as a 4-fold rise. Patients who had only the antibody rise but no flulike symptoms were not considered to have influenza-related illness. The virologic diagnosis was made by means of viral culture and/or a Rapidvue influenza test kit (Quidel, San Diego, CA) using a nasal or throat swab.

### Laboratory Investigations

At each visit, CD4 T cells were enumerated by standard flow cytometry and HIV VL was measured using the Roche Amplicor assay kit, version 1.5 (Roche Diagnostic Systems, Branchburg, NJ). Antibody responses to each of the 3 individual vaccine components were examined by the standard hemagglutinin inhibition (HAI) assay.<sup>20</sup> Titers  $\geq 40$  U were defined as protective, and a  $>4$ -fold rise in the antibody titer was considered an adequate response in previously antibody-negative patients.

For assessment of HA-specific CD4 T-cell responses, intracellular  $\gamma$ -interferon (IFN) production was examined by flow cytometry using the method described previously.<sup>21,22</sup> Because of the limited availability of peripheral blood mononuclear cells (PBMCs), we analyzed the H1-specific CD4 T cells only. Because fresh PBMCs must be used for this assay, as a result of a labor limitation, only the first 10 participants per day were examined on any particular day. Briefly, HA was purified from influenza virus strain, A/New Caledonia/20/99 (H1N1), as described previously.<sup>23</sup> PBMCs were isolated from the fresh heparinized blood and cultured ( $2 \times 10^6$  cells/mL) with diluted H1 plus anti-CD28 antibody (1  $\mu\text{g}/\text{mL}$ ) or medium alone for 16 hours at  $37^{\circ}\text{C}$ . Brefeldin A (10  $\mu\text{g}/\text{mL}$ ) was added to each sample in the final 5 hours of incubation. After 16 hours of stimulation, the cells were collected and stained

with anti-CD4 allophycocyanin antibody (Beckman Coulter, Fullerton, CA) and anti-CD69-fluorescent isothiocyanate antibody (Becton Dickinson). Subsequently, the cells were fixed and permeabilized to examine for the intracellular production of  $\gamma$ -IFN as described previously.<sup>21,22</sup> The flow cytometry analysis was performed by means of the FACSCalibur fluorescence-activated cell sorter with CellQuest software (BD Biosciences, San Jose, CA), and 10,000 CD4 T cells were collected for each analysis.

### Statistical Analysis

The data on HA-specific CD4 T cells are presented as the arithmetic mean  $\pm$  SEM. The data on anti-HA antibody titer are presented as the geometric mean. Statistical analyses were performed using StatView 5.0 software (Abacus Concepts, Berkeley, CA). Differences in the proportion of influenza virus infection between vaccinated and nonvaccinated groups were analyzed by the  $\chi^2$  test. Multiple logistic regression analysis was used to identify factors that contributed to protection against influenza illness. For the analyses of immune responses, participants were stratified by their CD4 count or HIV VL. Changes in antibody titer and HA-specific CD4 T cells were analyzed using the Kruskal-Wallis test or the Mann-Whitney *U* test. In all tests, a *P* value  $<0.05$  was considered significant.

## RESULTS

### Subjects

During the period of vaccination, 626 HIV-1-infected patients visited our clinic, and 332 of these received the vaccine, whereas 294 did not. Among them, 317 of those vaccinated and 87 of 100 approached to participate as nonvaccinated patients agreed to participate in the present study. Consequently, 76 patients dropped out of the study (55 of 317 vaccinated patients and 21 of 87 nonvaccinated patients). There were no characteristic differences at baseline between the analyzed and drop-out patients (data not shown). None of the patients dropped out from the study because of HIV-1 disease progression, and none received anticancer or immunosuppressive agents during this study. The final composition of the study group based on compliance with the study protocol, including visits on the fixed dates, was 262 vaccinated (82.6%) and 66 nonvaccinated (75.9%) patients (Fig. 1). Table 1 summarizes the baseline characteristics of the participants.

### Efficacy of Influenza Vaccine

The peak of the influenza epidemic of the 2002 through 2003 winter season in Japan was documented during the fourth week of January 2003 and was predominantly caused by influenza A/H3N2. The prevalence of influenza infection in this season was the third highest in the last decade.<sup>24</sup> In this study, 30 participants were diagnosed as having definitive influenza illness (5 patients with A/H1N1 strain, 16 with A/H3N2 strain, and 9 with B strain). Six patients were confirmed to have an influenza illness by flulike symptoms, positive viral cultures, positive influenza test kit results, and a  $>4$ -fold rise in antibody titer (1 with H1N1 strain, 1 with H3N2 strain, and






FIGURE 1. Profile of participants in this study.

4 with B strain); 3 by the symptoms, positive viral cultures, and antibody rise (2 with H1N1 strain and 1 with H3N2 strain); 5 by the symptoms, influenza test kit results, and antibody rise (1 with H1N1 strain, 2 with H3N2 strain, and 2 with B strain); and 16 by the antibody rise between the symptoms (1 with H1N1 strain, 12 with H3N2 strain, and 3 with B strain). In total, 16 of 262 vaccinated patients had influenza illness (6.1%, confidence interval [CI]: 0.04–0.1) and 14 of 66 nonvaccinated patients had the illness (21.2%, CI: 0.13–0.35). The difference in the incidence between the 2 groups was significant ( $P < 0.001$ ). The relative risk (RR) of influenza illness in vaccinated patients was 0.29 (CI: 0.14–0.55;  $P < 0.001$ ) compared with nonvaccinated patients (Table 2). Eight patients who had

a >4-fold rise in anti-H3 antibody titers between week 8 and week 16 without any clinical symptoms were not regarded as having influenza illness.

In patients with a CD4 count >200 cells/ $\mu$ L, the incidence of influenza illness in vaccinated patients (6.2%) was significantly lower than in nonvaccinated patients (21.0%) ( $P < 0.001$ ). Conversely, in patients with a CD4 count <200 cells/ $\mu$ L, the same comparison showed no significant difference. Nevertheless, the incidences of influenza illness in vaccinated (5.9%) and nonvaccinated (22.2%) patients were the same as the incidence in patients with a CD4 count >200 cells/ $\mu$ L. Therefore, this analysis had lack of power because of the small number of nonvaccinated patients in this stratum. In vaccinated and nonvaccinated patients, the differences in the incidence were significant in patients with HAART ( $P < 0.002$ ) and without HAART ( $P < 0.05$ ) (see Table 2). When CD4 count was entered as a continuous variable, multivariate analysis using the logistic regression model identified vaccination ( $P < 0.001$ ) and CD4 count ( $P < 0.05$ ) but not HIV VL as independent predictors of influenza illness in HIV-1-infected patients.

In patients with influenza illness, 4 of 16 vaccinated patients and 4 of 14 nonvaccinated patients received an anti-influenza drug. None of the patients with influenza illness developed pneumonia that required treatment or hospitalization during the study period. Vaccination did not significantly change the HIV VL or CD4 count at weeks 8 and 16.

### Anti-Hemagglutinin Antibody Responses Before and After Vaccination

HAI antibody titers against HA antigens (H1 and H3) were tested before and 8 and 16 weeks after vaccination (Table 3). To evaluate the effect of the single-shot influenza vaccine, subjects were divided into 2 groups based on the HAI titer before vaccination: the baseline HAI antibody-negative and antibody-positive groups. Furthermore, we excluded from this

TABLE 1. Baseline Clinical and Immunologic Characteristics of Participants\*

	Vaccinated	Nonvaccinated	P
No. participants (n)	262	66	—
Male/female ratio	7:1	15:1	n.s.
Median age, y (range)	41 (20–78)	40 (20–61)	n.s.
Received HAART (%)	75.2%	72.3%	n.s.
Median CD4 count at vaccination, $\mu$ L (range)	380 (40–1137)	374 (66–1025)	n.s.
Median CD8 count at vaccination, $\mu$ L (range)	778 (54–2649)	751 (163–1929)	n.s.
Median HIV VL at vaccination, log <sub>10</sub> /mL (range)	2.5 (1.5–6.2)	2.5 (1.5–6.4)	n.s.
Prior anti-H1 antibody-positive (%)	29.4%	26.4%	n.s.
Prior anti-H3 antibody-positive (%)	32.3%	30.3%	n.s.

\*All participants were Japanese. n.s. indicates not significant.

**TABLE 2.** Incidence of Influenza Illness

	Vaccinated		Nonvaccinated		$\chi^2$ Test
	Illness/Patients	Rate (95% CI)	Illness/Patients	Rate (95% CI)	
All patients	16/262	6.1% (0.04–0.1)	14/66	21.2% (0.13–0.35)	$P < 0.001$
CD4 count					
<200 cells/ $\mu$ L	3/51	5.9% (0.02–0.15)	2/9	22.2% (0.06–0.55)	n.s.
$\geq$ 200 cells/ $\mu$ L	13/211	6.2% (0.03–0.1)	12/57	21.0% (0.12–0.33)	$P < 0.001$
HAART					
+	12/197	6.1% (0.04–0.1)	10/48	20.8% (0.11–0.34)	$P < 0.002$
–	4/65	6.2% (0.02–0.14)	4/18	22.2% (0.09–0.45)	$P < 0.05$

Incidence of influenza illness in healthy immunized controls was 3.8% (1 of 26, 95% CI: 0.01–0.19).  
n.s. indicates not significant.

analysis the 13 patients who received the vaccination but had influenza illness (5 with H1N1 strain and 8 with H3N2 strain) during the study period so as to evaluate the antibody responses by the vaccination. The 8 patients who showed a >4-fold rise in anti-H3 antibody titers between week 8 and week 16 without any clinical symptoms were also excluded from this analysis, because the antibody rise in these cases was thought to be caused by influenza virus but not by vaccination. In the baseline HAI-negative group, the antibody responses to both antigens were significantly different compared with those in stratified HIV-1-infected patients by CD4 count (<200 cells/ $\mu$ L and  $\geq$ 200 cells/ $\mu$ L;  $P < 0.05$ ) at week 8 and week 16. These titers were low compared with those of the healthy immunized controls in both strata, however. In those with a CD4 count <200 cells/ $\mu$ L, 12 (27.9%) of 43 patients and 12 (32.4%) of 37 patients showed more than a 4-fold rise in the antibody responses against anti-H1 and anti-H3, respectively. In contrast, in those patients with a CD4 count

>200 cells/ $\mu$ L, 62 (44.6%) of 139 patients and 61 (46.9%) of 130 patients showed a >4-fold rise in the antibody responses against anti-H1 and anti-H3, respectively. Although differences in the percentages of patients who showed both anti-H1 ( $P = 0.05$ ) and anti-H3 ( $P = 0.12$ ) antibody responses of the different CD4 strata were only marginal, there was a tendency for the single-shot vaccination to be more effective in terms of antibody responses in patients with a CD4 count >200 cells/ $\mu$ L. The antibody responses in both groups were not influenced by HIV VL (<100 copies/mL and  $\geq$ 100 copies/mL; data not shown).

In the baseline HAI antibody-positive group, HAI titers to both antigens remained high and the sustainability of the antibody titers in HIV-1-infected patients was similar to those of the healthy controls, irrespective of CD4 counts (see Table 3). In terms of the antibody rise, in those with a CD4 count <200 cells/ $\mu$ L, 5 of 8 patients and 1 of 6 patients showed more than a 4-fold rise in the antibody response against anti-H1 and

**TABLE 3.** Anti-HA Antibody Responses After Vaccination in Baseline Anti-HA Antibody-Negative and Positive Individuals

	Anti-HA Antibody Responses* After Vaccination in HIV-1 Patients†						Healthy Immunized Controls	
	Stratum 1 (CD4 count <200 cells/ $\mu$ L)			Stratum 2 (CD4 count $\geq$ 200 cells/ $\mu$ L)			Week 0	Week 8
	Week 0	Week 8	Week 16	Week 0	Week 8	Week 16		
Baseline anti-H1 Ab-negative	n = 43			n = 139			n = 4	
Anti-H1 Ab responses	<10	26‡ (10–1280)	23‡ (10–1280)	<10	42 (10–1280)	36 (10–1280)	<10	135 (40–320)
Baseline anti-H3 Ab-negative	n = 37			n = 130			n = 4	
Anti-H3 Ab responses	<10	25‡ (10–640)	23‡ (10–1280)	<10	34 (10–1280)	32 (10–640)	<10	135 (40–320)
Baseline anti-H1 Ab-positive	n = 8			n = 67			n = 22	
Anti-H1 Ab responses	44 (20–320)	353 (40–1280)	208 (80–160)	54 (20–1280)	158 (20–1280)	143 (20–1280)	80 (20–640)	86 (20–640)
Baseline anti-H3 Ab-positive	n = 6			n = 73			n = 22	
Anti-H3 Ab responses	32 (20–80)	46 (20–160)	71 (20–640)	41 (20–1280)	105 (20–1280)	87 (10–1280)	59 (20–320)	66 (20–320)

\*The data presented here are the geometric mean of anti-HA antibody titer. Range of the absolute titer is shown in parentheses.

†To analyze antibody responses to vaccination, patients with influenza infection were excluded from this analysis.

‡ $P < 0.05$  compared with the respective value of stratum 2.

Ab indicates antibody. Change of the antibody titer from <10 to 40 U was considered a 4-fold rise.

anti-H3. Conversely, in those with a CD4 count >200 cells/ $\mu$ L, 16 of 67 patients and 19 of 73 patients showed more than a 4-fold rise.

### Anti-H1 and Anti-H3 Antibody Responses in Patients With Influenza Illness Despite Vaccination

A total of 16 patients (5 with H1N1 strain, 8 with H3N2 strain, and 3 with B strain) had influenza illness among the vaccinated group during this study period. In the 5 patients with H1N1 illness, 3 were baseline anti-H1 antibody-negative and 2 had the antibody. Among the 3 baseline anti-H1 antibody-negative patients, 2 were infected before week 8 and 1 was infected after week 8. In the patient infected after week 8, no anti-H1 antibody was detected at week 8. In each of the 2 baseline anti-H1 antibody-positive patients, the titer was 20 U. Both patients were infected before week 8. In the 8 patients with H3N2 illness, 6 were baseline anti-H3 antibody-negative and 2 were positive for the antibody. In the 6 baseline anti-H3 antibody-negative patients, all were infected after week 8. Among these 6 patients, 4 were negative for anti-H3 antibody at week 8, whereas 2 had a 4-fold rise in the antibody before infection. In each of the 2 baseline anti-H3 antibody-positive patients, the titer was 20 U. Both patients were infected after week 8. Anti-H3 antibody at week 8 was increased to 40 U (a 2-fold rise) only in 1 patient. Overall, among the 9 infected patients (1 with H1N2 strain and 8 with H3N2 strain) in whom the antibody responses at week 8 could be evaluated, only 2 had a >4-fold rise of the antibody response before infection.

### H1-Specific CD4 T-Cell Response Before and After Vaccination in Baseline Anti-H1 Antibody-Negative Subjects


H1-specific CD4 T-cell responses at week 8 were HIV VL dependent ( $P < 0.005$ ) but not CD4 count dependent (Fig. 2A). Therefore, H1-specific CD4 T-cell responses were significantly increased by vaccination in HAART-treated patients ( $P = 0.001$ ), because HIV VL was decreased by HAART (see Fig. 2B). In contrast, responses of HAI antibody titer were not different between HAART-treated and antiretroviral-naive patients (see Fig. 2C).

### Comparison of Immune Responses to H1 Antigen at Week 8 Between Influenza A/H1N1-Infected and -Uninfected Patients

Five individuals were infected with influenza A/H1N1 during this season. HAI antibody titers at 8 weeks after the vaccination were not different between the infected and uninfected individuals. In contrast, H1-specific CD4 T-cell responses at week 8 were significantly low in the infected persons compared with those in the uninfected persons ( $P < 0.05$ ; Fig. 3).

## DISCUSSION


Our prospective study confirmed many conclusions of previously reported small studies. First, we confirmed the protective effect of influenza vaccine in HIV-1-infected patients.<sup>8-15</sup> Second, anti-H1-specific and anti-H3-specific antibody responses



**FIGURE 2.** H1-specific CD4<sup>+</sup> T-cell responses after influenza vaccine in baseline anti-H1 antibody-negative patients. **A**, Correlation of plasma HIV-1 viral load (HIV VL) and percentage of H1-specific CD4<sup>+</sup> T cells. \*H1-specific CD4<sup>+</sup> T cells ( $\blacktriangle$ ) were significantly fewer in number in subjects with an HIV VL >10,000 copies/mL ( $P < 0.005$ ). The number of samples with an HIV VL <100 copies/mL was 53, there were 19 samples with 100 to 10,000 copies/mL, and there were 11 samples with >10,000 copies/mL, because H1-specific CD4<sup>+</sup> T cells were only examined in the first 10 samples per day as stated in the text. **B**, Changes in the percentage of H1-specific CD4<sup>+</sup> T cells in highly active antiretroviral therapy (HAART)-treated; ( $\circ$ ;  $n = 63$ ) and antiretroviral-naive patients ( $\bullet$ ;  $n = 12$ ). †HAART-treated patients had significantly greater numbers of H1-specific CD4<sup>+</sup> T cells at week 8 ( $P < 0.01$ ) than antiretroviral-naive patients. **C**, Changes in anti-H1 antibody titer in HAART-treated ( $\circ$ ;  $n = 131$ ) and antiretroviral-naive patients ( $\bullet$ ;  $n = 35$ ). Anti-H1 antibody responses were similar in both groups. Data are mean  $\pm$  SEM.

were examined in HIV-1-infected patients after vaccination, and the responses were confirmed to be dependent on CD4 counts.<sup>8-11</sup>

To clarify the efficacy of a single-shot vaccination, we divided the participants by the positivity of anti-H1- and anti-H3-specific antibodies before vaccination and found that in



**FIGURE 3.** H1-specific CD4<sup>+</sup> T cells and anti-H1 antibody responses at week 8 after vaccination in influenza A/H1N1-infected patients. Five vaccinated individuals were infected with influenza A/H1N1. A, Percentage of H1-specific CD4<sup>+</sup> T-cell responses in infected (○; n = 4) and noninfected (●; n = 119) individuals. \*H1-specific CD4<sup>+</sup> T cells responded better to influenza A/H1N1 in noninfected patients than in infected patients ( $P < 0.05$ ). One sample of 5 influenza A/H1N1-infected individuals was not examined because the sample was not among the first 10 samples per day as stated in the text. B, Anti-H1 antibody titers in infected (○; n = 5) and noninfected (●; n = 249) individuals. The anti-H1 antibody response at week 8 was similar in both groups. Data are mean  $\pm$  SEM.

baseline antibody-negative HIV-1-infected patients, the antibody responses to the single-shot vaccination were less effective than those in healthy patients. In contrast, however, in baseline antibody-positive HIV-1-infected patients, the antibody responses were similar or more effective than those in the healthy controls and the titers exceeded  $>40$  U in most cases, irrespective of CD4 count. Previous studies demonstrated that an antibody titer  $>40$  U could be used as an index of vaccine protection.<sup>12,25</sup> In our study, the antibody titer was  $<40$  U in most patients who became infected with influenza. Considered together, these results suggest that the antibody response may support the clinical efficacy of influenza vaccination. Kroon et al<sup>8</sup> reported that postvaccination antibody titers were higher in previously vaccinated HIV-1-infected patients than in nonvaccinated patients, although the difference was not significant. In the present study, the antibody titers showed a better response in individuals positive at baseline for anti-HA antibody than in those negative for the antibody. Furthermore, the response was well sustained, irrespective of CD4 count. Thus, it is conceiv-

able that annual vaccination is specifically important for all HIV-1-infected patients. Sustainability of the antibody titer raised by the vaccination is to be followed in a future study.

In the immunologic part of our study, we examined antibody responses and specific CD4 T cells. The antibody response was almost the same as that reported previously<sup>8,9</sup>; the response correlated with the CD4 count. In contrast, specific CD4 T cells were much more influenced by HIV VL than by CD4 count.<sup>1,8-15</sup> Therefore, the specific CD4 T cells were higher in patients treated with HAART than in those untreated. This result indicates that HAART improves HA-specific CD4 T cells like in other infections,<sup>21</sup> or, in other words, the heightened cellular response to the influenza vaccine suggests functional reconstitution of the immune system after HAART.

Our data indicate that the specific CD4 T-cell responses may be related to HIV VL. The specific CD4 T-cell response needs antigen presentation by dendritic cells.<sup>26</sup> HIV-1 infection impairs the function of antigen presentation of dendritic cells.<sup>27</sup> Therefore, specific CD4 T-cell responses may be profoundly decreased in patients with a high HIV VL.

It is interesting to note that the percentage of H1-specific CD4 T cells at week 8 was significantly lower in influenza A/H1N1-infected patients. It is conceivable that the response of HA-specific CD4 T cells at week 8 can predict the efficacy of influenza vaccine. Influenza-specific CD4 T cells provide help (as Th cells) to B cells for the production of antibody to influenza HA and neuraminidase<sup>28,29</sup> and also promote the generation of virus-specific CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs).<sup>26,30-33</sup> Therefore, the specific CD4 T cell must have a protective role. This concept would be more reliable if we had analyzed H3-specific CD4 T cells rather than H1-specific CD4 T cells, because influenza A/H3N2 was the predominant subtype in this season. Further studies are necessary to elucidate this point.

Our study was designed as a prospective but nonrandomized study, because influenza vaccine has been already recommended for HIV-1-infected patients.<sup>7</sup> Practically, the number of nonvaccinated patients who did not participate in our study was higher than that of vaccinated patients (13% of nonvaccinated patients vs. 4.5% of vaccinated patients), and the violation rate of the study protocol was higher in nonvaccinated patients than in vaccinated patients (24.1% vs. 17.4%). Thus, 262 (78.9%) of 332 vaccinated patients and 66 (66%) of 100 nonvaccinated patients were analyzed in this study. Although a relatively high proportion of patients failed to complete the protocol, the main reason for the drop out may have been the lack of incentives and the need to visit our clinic on a fixed date for blood sampling. The vaccinated and nonvaccinated groups were well balanced in terms of baseline characteristics, however. Finally, we believe that the selection bias of participants, if any, is negligible.

In conclusion, our prospective study in a large population demonstrated that influenza vaccine provides protection of HIV-1-infected patients. In baseline antibody-negative patients, the antibody responses to the vaccination were significant in those patients with a CD4 count  $>200$  cells/ $\mu$ L compared with those with a CD4 count  $<200$  cells/ $\mu$ L. In contrast, in baseline antibody-positive patients, good antibody responses were observed, irrespective of CD4 counts. Annual vaccination of